GO:0001963 synaptic transmission, dopaminergic: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001963 synaptic transmission, dopaminergic describes the vesicular release of dopamine from a presynapse, activation of postsynaptic dopamine receptors, and the resulting changes in postsynaptic membrane potential and ionic composition.
• Dopaminergic synaptic transmission is a key modulator of reward, mood, motor control, and cognition, and its dysfunction is implicated in bipolar disorder, addiction, and other neuropsychiatric conditions [1,5].
• The process is regulated by presynaptic autoreceptors, dopamine transporters, and interactions with other neurotransmitter systems, including oxytocin and endocannabinoids [2,4].
• Key genes include tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (DDC), vesicular monoamine transporter 2 (SLC18A2), dopamine transporter (SLC6A3), and dopamine receptors (DRD1-DRD5) [1,5].
• Experimental models such as knockout mice, point-mutation knock-ins, and overexpression systems are essential to dissect the causal roles of these genes in dopaminergic transmission [7,8].
• CRISPR-based editing enables precise interrogation of dopaminergic synaptic transmission in health and disease, from single-gene knockouts to library screening for novel regulators [1,7].
Description
Dopaminergic synaptic transmission is a fundamental biological process that underlies motor control, reward processing, mood regulation, and cognition. The Gene Ontology term GO:0001963, synaptic transmission, dopaminergic, captures the entire sequence of events from the vesicular release of dopamine at the presynapse to the activation of dopamine receptors on the postsynaptic cell and the subsequent changes in membrane potential and ionic composition. This process is essential for normal brain function, and its dysregulation is associated with a wide range of neurological and psychiatric disorders, including bipolar affective disorder, addiction, and movement disorders [1,5]. Researchers study dopaminergic synaptic transmission to understand how dopamine modulates neural circuits and behavior. The dopamine hypothesis of bipolar affective disorder, for example, posits that altered dopaminergic transmission contributes to mood episodes, and treatments targeting this system remain central to clinical management. Moreover, dopaminergic signaling interacts with other neurotransmitter systems, such as oxytocin and endocannabinoids, to fine-tune synaptic strength and behavioral outcomes [2,4]. Given its broad impact, dissecting the molecular players and regulatory mechanisms of dopaminergic synaptic transmission is critical. This article provides a comprehensive overview of GO:0001963, including its definition, core mechanisms, key genes, disease relevance, and modern research methods, with a focus on CRISPR-based approaches for functional genomics.
synaptic transmission, dopaminergic At A Glance
| GO ID | GO:0001963 |
|---|---|
| GO term | synaptic transmission, dopaminergic |
| Ontology | biological_process |
| Synonym | dopaminergic synaptic transmission |
| Major function | Vesicular release of dopamine and activation of postsynaptic dopamine receptors, modulating postsynaptic membrane potential and ionic composition |
| Related neurotransmitters | Dopamine; interactions with oxytocin and endocannabinoids [2,4] |
| Key brain regions | Prefrontal cortex, striatum, globus pallidus, hippocampus, orexin neurons [2,3,4,7] |
| Associated diseases | Bipolar affective disorder, addiction, movement disorders [1,5] |
What Is GO:0001963?
GO:0001963 synaptic transmission, dopaminergic is defined as the vesicular release of dopamine from a presynapse, across a chemical synapse, followed by activation of dopamine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.
Why Is synaptic transmission, dopaminergic Important in Cell Biology?
Dopaminergic synaptic transmission is central to numerous physiological processes, including reward, motivation, motor control, and mood regulation. Its dysfunction is a hallmark of several high-impact neuropsychiatric and neurological disorders, such as bipolar affective disorder, substance use disorders, and Parkinson's disease [1,5]. Understanding the precise molecular mechanisms of GO:0001963 is therefore essential for developing targeted therapeutic strategies and for interpreting the effects of genetic variants that alter dopamine signaling.
• Dopaminergic transmission modulates reward-seeking and addiction behaviors, making it a key target for substance use disorder research.
• Altered dopaminergic synaptic transmission is implicated in the pathophysiology of bipolar affective disorder.
• Oxytocin exerts antidepressant-like effects by potentiating dopaminergic synaptic transmission in the medial prefrontal cortex.
• Dopamine bidirectionally modulates excitatory synaptic transmission in orexin neurons, linking dopamine to sleep/wake regulation.
• Cannabinoid-induced depression of synaptic transmission switches to stimulation when dopaminergic tone is increased in the globus pallidus, highlighting dopamine's role in motor control.
• Dopaminergic modulation of afferent synaptic transmission occurs in sensory systems such as the semicircular canals of frogs.
• Exercise-induced alterations in dopaminergic synaptic transmission modulate hippocampal long-term potentiation, linking dopamine to learning and memory.
• Combining group I mGlu receptor antagonists with dopaminergic agonists strengthens corticostriatal synaptic transmission, with implications for motor disorders.
What Happens During synaptic transmission, dopaminergic?
Dopamine Synthesis and Vesicular Packaging
In simple terms: Dopamine is made inside the neuron and packed into tiny bubbles called vesicles.
Dopamine is synthesized in the presynaptic neuron from tyrosine by tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (DDC). It is then transported into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2, encoded by SLC18A2). This packaging is essential for subsequent release.
Action Potential Arrival and Vesicle Fusion
In simple terms: When an electrical signal reaches the nerve ending, it triggers the vesicles to fuse with the membrane and release dopamine.
Evoked transmission starts with the arrival of an action potential at the presynapse, which depolarizes the terminal and opens voltage-gated calcium channels. Calcium influx triggers the fusion of dopamine-containing vesicles with the presynaptic membrane, releasing dopamine into the synaptic cleft.
Postsynaptic Receptor Activation
In simple terms: Dopamine crosses the gap and binds to receptors on the next neuron, changing its electrical state.
Released dopamine binds to dopamine receptors (D1-like: DRD1, DRD5; D2-like: DRD2, DRD3, DRD4) on the postsynaptic membrane. This activation leads to changes in the postsynaptic membrane potential and ionic composition, either exciting or inhibiting the postsynaptic cell depending on the receptor subtype and cell type [1,3].
Modulation by Other Neurotransmitters
In simple terms: Other chemicals can turn the dopamine signal up or down.
Dopaminergic synaptic transmission is modulated by various factors. For example, oxytocin potentiates dopaminergic synaptic transmission in the medial prefrontal cortex, exerting antidepressant-like effects. Endocannabinoids can depress or stimulate synaptic transmission depending on dopaminergic tone in the globus pallidus. Additionally, group I mGlu receptor antagonists combined with dopaminergic agonists strengthen corticostriatal synaptic transmission.
Reuptake and Termination
In simple terms: Dopamine is quickly removed from the gap to stop the signal.
The action of dopamine is terminated primarily by reuptake into the presynaptic neuron via the dopamine transporter (DAT, encoded by SLC6A3). This process is crucial for maintaining precise temporal control of dopaminergic signaling and is a target of psychostimulants [1,5].
Key Genes Involved in GO:0001963 synaptic transmission, dopaminergic
The following genes encode proteins that are essential for dopamine synthesis, packaging, release, reception, and reuptake, and are frequently studied in the context of GO:0001963.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TH | Tyrosine hydroxylase, rate-limiting enzyme in dopamine synthesis | Knockout causes dopamine deficiency; target for Parkinson's disease research |
| DDC | Aromatic L-amino acid decarboxylase, converts L-DOPA to dopamine | Mutations cause aromatic L-amino acid decarboxylase deficiency |
| SLC18A2 | Vesicular monoamine transporter 2 (VMAT2), packages dopamine into vesicles | Essential for vesicular release; knockout abolishes dopaminergic transmission |
| SLC6A3 | Dopamine transporter (DAT), reuptakes dopamine from synapse | Target of psychostimulants; knockout leads to elevated dopamine [1,5] |
| DRD1 | Dopamine receptor D1, postsynaptic excitatory signaling | Modulates reward and motor function; knockout alters synaptic plasticity |
| DRD2 | Dopamine receptor D2, presynaptic autoreceptor and postsynaptic receptor | Key target of antipsychotics; knockout affects locomotion |
| DRD3 | Dopamine receptor D3, modulates reward and cognition | Implicated in addiction and schizophrenia |
| DRD4 | Dopamine receptor D4, modulates attention and reward | Polymorphisms linked to novelty seeking |
| DRD5 | Dopamine receptor D5, excitatory signaling | Less studied; may modulate hippocampal function |
| COMT | Catechol-O-methyltransferase, degrades dopamine in prefrontal cortex | Val158Met polymorphism affects cognition |
| MAOA | Monoamine oxidase A, degrades dopamine | Knockout increases dopamine levels; linked to aggression |
| MAOB | Monoamine oxidase B, degrades dopamine | Inhibitors used in Parkinson's disease |
| SLC6A2 | Norepinephrine transporter, also transports dopamine in some regions | Contributes to dopamine clearance in prefrontal cortex |
| GCH1 | GTP cyclohydrolase 1, cofactor for TH | Mutations cause dopa-responsive dystonia |
| SNCA | Alpha-synuclein, regulates vesicle trafficking and release | Mutations cause familial Parkinson's disease |
| LRRK2 | Leucine-rich repeat kinase 2, modulates vesicle trafficking | Mutations linked to Parkinson's disease |
| PARK7 | DJ-1, protects against oxidative stress in dopaminergic neurons | Mutations cause early-onset Parkinson's disease |
| PINK1 | PTEN-induced kinase 1, mitochondrial quality control | Mutations cause recessive Parkinson's disease |
How Is synaptic transmission, dopaminergic Regulated?
Dopaminergic synaptic transmission is tightly regulated at multiple levels. Presynaptic D2 autoreceptors (DRD2) provide negative feedback, inhibiting dopamine synthesis and release when extracellular dopamine levels are high. The dopamine transporter (DAT) controls the duration and amplitude of dopamine signals by rapid reuptake [1,5]. Additionally, other neurotransmitter systems modulate dopaminergic transmission: oxytocin potentiates it in the medial prefrontal cortex, while endocannabinoids can depress or stimulate it depending on dopaminergic tone. Group I mGlu receptor antagonists enhance dopaminergic agonist-induced strengthening of corticostriatal synapses. These regulatory mechanisms ensure precise spatiotemporal control of dopamine signaling.
synaptic transmission, dopaminergic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A3 | Dopamine transporter deficiency syndrome; altered dopamine clearance | Knockout mouse; point-mutation knock-in of patient variants |
| DRD2 | Bipolar disorder; antipsychotic response | Conditional knockout; overexpression in striatum |
| SNCA | Parkinson's disease; alpha-synuclein aggregation | Knock-in of A53T mutation; overexpression |
| LRRK2 | Parkinson's disease; kinase hyperactivity | G2019S knock-in mouse |
| TH | Dopa-responsive dystonia; dopamine deficiency | Knockout; conditional rescue |
Bipolar Affective Disorder
The dopamine hypothesis of bipolar affective disorder posits that dysregulated dopaminergic synaptic transmission contributes to mood episodes. Alterations in dopamine release, receptor sensitivity, and transporter function have been observed in patients, and many effective treatments target the dopamine system.
Addiction and Reward Disorders
Dopaminergic synaptic transmission in reward circuits is critically involved in substance use disorders. Drugs of abuse increase dopamine release, and chronic exposure leads to neuroadaptations that drive addiction. Cannabinoids, for example, interact with dopamine release to modulate reward seeking.
Parkinson's Disease and Movement Disorders
Degeneration of dopaminergic neurons in the substantia nigra leads to profound deficits in dopaminergic synaptic transmission, causing the motor symptoms of Parkinson's disease. Genes such as SNCA, LRRK2, PINK1, and PARK7 are linked to familial forms of the disease.
From synaptic transmission, dopaminergic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DAT alter dopaminergic tone and behavior? | SLC6A3 knockout mouse |
| How does a patient variant in DRD2 affect receptor function? | DRD2 point-mutation knock-in |
| Can overexpression of TH rescue dopamine deficiency? | TH overexpression via viral vector or transgenic mouse |
| What is the role of SNCA in vesicle release? | SNCA knockout and A53T knock-in |
| Does oxytocin potentiate dopaminergic transmission? | Oxytocin receptor knockout; mPFC-specific manipulation |
| How does exercise alter dopaminergic transmission? | Selectively bred high voluntary wheel running mice |
How to Study the synaptic transmission, dopaminergic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Postsynaptic currents and membrane potential | Measure dopaminergic modulation of synaptic transmission |
| Fast-scan cyclic voltammetry | Real-time dopamine release | Assess evoked dopamine dynamics in brain slices |
| Microdialysis | Extracellular dopamine levels | Monitor dopamine changes in vivo during behavior |
| Immunohistochemistry | Localization of dopamine receptors and transporters | Map expression in brain regions |
| CRISPR knockout | Loss-of-function of candidate genes | Determine necessity of genes for dopaminergic transmission |
| CRISPR knock-in | Introduction of specific mutations | Model patient variants in dopamine-related genes |
| Optogenetics | Selective activation of dopaminergic neurons | Evoke dopamine release with temporal precision |
| RNA-seq | Transcriptomic changes | Identify gene expression changes after manipulation |
Electrophysiology
Patch-clamp recordings and amperometry are used to measure dopamine release and postsynaptic currents. For example, bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons was demonstrated using electrophysiology.
Fast-Scan Cyclic Voltammetry
This technique detects real-time dopamine release in brain slices or in vivo, providing high temporal resolution of dopaminergic transmission dynamics.
Genetic Knockout and Knock-in Models
CRISPR-generated knockout and knock-in mice are essential to dissect the causal roles of genes such as SLC6A3, DRD2, and SNCA in dopaminergic synaptic transmission [1,7].
Pharmacological Modulation
Agonists and antagonists targeting dopamine receptors, transporters, and interacting pathways (e.g., mGlu receptors, cannabinoid receptors) are used to probe synaptic transmission [4,8].
How CRISPR Can Be Used to Study GO:0001963 synaptic transmission, dopaminergic
Knockout
CRISPR knockout of genes such as SLC6A3, DRD2, or TH in cell lines and animal models abolishes or severely reduces dopaminergic synaptic transmission, allowing researchers to test necessity. For example, DAT knockout mice exhibit elevated dopamine and altered behaviors.
Point Mutation
Point mutations can be introduced to model patient-specific variants, such as the DRD2 Val158Met or SNCA A53T, to study their effects on receptor function or protein aggregation in the context of dopaminergic transmission.
Knock-in
Knock-in of reporter tags (e.g., GFP) or disease-associated mutations into endogenous loci enables real-time visualization of dopamine release and receptor trafficking, as well as physiological studies of mutant proteins.
Overexpression
Overexpression of genes like TH or SNCA via CRISPR activation or transgenic approaches can model dopamine excess or synucleinopathies, providing insights into gain-of-function mechanisms in dopaminergic transmission.
How EDITGENE Supports synaptic transmission, dopaminergic Research
Researchers studying synaptic transmission, dopaminergic-related genes often need to determine whether a candidate gene is causally involved in dopamine release, receptor signaling, or reuptake. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from single-gene knockout to high-throughput library screening.
Contact EDITGENE today to design your custom CRISPR model for synaptic transmission, dopaminergic research.
Frequently Asked Questions About synaptic transmission, dopaminergic
What is GO:0001963 synaptic transmission, dopaminergic?
GO:0001963 is a Gene Ontology biological process term describing the vesicular release of dopamine from a presynapse, activation of postsynaptic dopamine receptors, and the resulting changes in postsynaptic membrane potential and ionic composition.
What genes are involved in synaptic transmission, dopaminergic?
Key genes include TH, DDC, SLC18A2, SLC6A3, DRD1-DRD5, COMT, MAOA, MAOB, and SNCA, among others.
How is dopaminergic synaptic transmission regulated?
It is regulated by presynaptic D2 autoreceptors, dopamine transporters, and modulation by other neurotransmitters such as oxytocin and endocannabinoids [1,2,4].
What diseases are associated with impaired dopaminergic synaptic transmission?
Bipolar affective disorder, addiction, Parkinson's disease, and other movement disorders are linked to altered dopaminergic transmission [1,5].
What methods are used to study dopaminergic synaptic transmission?
Electrophysiology, fast-scan cyclic voltammetry, microdialysis, CRISPR knockout/knock-in, and optogenetics are commonly used [1,3,5].
How does oxytocin affect dopaminergic synaptic transmission?
Oxytocin potentiates dopaminergic synaptic transmission in the medial prefrontal cortex, exerting antidepressant-like effects.
Can cannabinoids modulate dopaminergic synaptic transmission?
Yes, cannabinoids can depress or stimulate synaptic transmission depending on dopaminergic tone, as shown in the globus pallidus.
What is the role of dopamine in reward and addiction?
Dopamine release in reward circuits is central to reward seeking and addiction, with cannabinoids influencing this process.
How does exercise affect dopaminergic synaptic transmission?
Exercise-induced alterations in dopaminergic synaptic transmission modulate hippocampal long-term potentiation in mice.
What CRISPR models are available for studying dopaminergic transmission?
Knockout, point mutation, knock-in, and overexpression models can be generated for genes like SLC6A3, DRD2, and SNCA to study their roles.
Conclusion
GO:0001963 synaptic transmission, dopaminergic is a fundamental biological process that governs dopamine release, receptor activation, and downstream signaling in the brain. Its dysregulation contributes to major neuropsychiatric and neurodegenerative disorders, making it a critical area of research. By leveraging CRISPR-based models and advanced methodologies, researchers can dissect the precise molecular mechanisms and identify novel therapeutic targets. EDITGENE offers comprehensive services to support these efforts, from gene editing to bioinformatics.
References
- 1. Ashok AH et al.. 2017. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.. Mol Psychiatry 22(5):666-679 PMID: 28289283
- 2. Li Q et al.. 2020. Oxytocin Exerts Antidepressant-like effect by potentiating dopaminergic synaptic transmission in the mPFC.. Neuropharmacology 162:107836 PMID: 31682854
- 3. Alberto CO et al.. 2006. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons.. J Neurosci 26(39):10043-50 PMID: 17005867
- 4. Caballero-Florán RN et al.. 2016. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.. Neuropharmacology 110(Pt A):407-418 PMID: 27506997
- 5. Peters KZ et al.. 2021. A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking and Addiction.. Cold Spring Harb Perspect Med 11(1) PMID: 31964646
- 6. Andrianov GN et al.. 2009. Dopaminergic modulation of afferent synaptic transmission in the semicircular canals of frogs.. Neurosignals 17(3):222-8 PMID: 19546593
- 7. Phan JM et al.. 2024. Hippocampal long-term potentiation is modulated by exercise-induced alterations in dopaminergic synaptic transmission in mice selectively bred for high voluntary wheel running.. Restor Neurol Neurosci 42(3-4):193-208 PMID: 39973602
- 8. Burguière A et al.. 2013. Combination of group I mGlu receptors antagonist with dopaminergic agonists strengthens the synaptic transmission at corticostriatal synapses in culture.. Neuropharmacology 66:151-7 PMID: 22465815
